Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
For many people, the first practical question about a new treatment is not only whether it makes sense medically, but also how it will fit into real life. Can you keep working? Do you need to stay in a hospital? If you live abroad or far from Osaka, how many trips might be involved? This article walks through those practical questions for NK (natural killer) cell therapy at Grand Green Osaka Umekita Clinic, so that you can arrive at your consultation with a clearer picture and better questions.
The short answer: it is designed as an outpatient treatment
NK cell therapy is an immune cell therapy in which your own NK cells are activated and expanded outside the body and then returned by intravenous (IV) infusion. According to the clinic’s treatment information, the process relies on a standard blood draw and an IV infusion, with no hospitalization. That means many patients can continue much of their daily routine between visits.
However, “outpatient” does not mean “no planning needed.” The exact number of visits, the interval between them, and how you might feel afterward depend on your own situation and on your doctor’s judgment. Temporary fever or fatigue may occur after treatment, so it is sensible not to schedule demanding commitments immediately afterward until you know how you respond.
Understanding the two types of visits
It helps to think of the treatment as two kinds of appointments. The first is the blood draw, during which the blood that will be used to obtain NK cells is collected. The second is the infusion, when the activated and expanded NK cells are returned to you through an IV drip. Between them, the cells are processed at a specialized cell processing facility, which takes time.
Because the processing step happens between your visits, the schedule is not something you can compress by simply staying longer in one trip. This is one of the most important points for people traveling from overseas. When you speak with the clinic, ask how the blood draw and infusion are spaced, whether any steps can be coordinated around a single trip, and what happens if your travel dates change.
- How many blood draws and infusions are usually discussed for a person in your situation?
- How much time typically passes between a blood draw and the related infusion?
- How long should you plan to remain at the clinic on each visit day?
- What is the process if a visit has to be postponed because of illness or travel disruption?
Work, family, and everyday life
Since there is no hospital stay, many people find that treatment visits can be arranged around work and family responsibilities. Still, individual experiences differ. Some people feel entirely normal after an infusion, while others may notice a temporary fever or tiredness. Neither pattern predicts how the therapy will work for you, and you should not draw conclusions from other people’s accounts.
If you are also undergoing surgery, chemotherapy, or radiation therapy elsewhere, your calendar may already be full. NK cell therapy is intended to be used alongside, not instead of, these standard treatments, and the clinic can coordinate with the institution providing your standard care. Even so, the timing of each treatment should be agreed upon with your oncologist and the clinic together. Standard cancer treatment remains the foundation of care, and NK cell therapy is considered as an additional option, not a replacement.
Planning travel to Osaka as an international patient
Osaka is a major hub, and Umeda, where the clinic is located, is well connected by rail and close to major stations. For people arriving from abroad, that can simplify getting to and from appointments. The clinic also provides an information page for international patients, so you can review the basics in your own language before making contact.
Before you book flights or accommodation, it is wise to speak with the clinic first. Confirm whether an initial consultation can take place remotely, so that you can get an early sense of whether treatment may be appropriate for you before committing to travel. Ask which documents to bring, such as your diagnosis, treatment history, and recent test results, ideally with translations or in a form your doctor can review. Keeping flexible travel arrangements where possible is also helpful, because the timing of treatment steps may shift.
- Ask whether a consultation can be held online or by phone before you travel.
- Prepare a summary of your diagnosis, medications, and current treatments.
- Check with your home doctor about any travel restrictions related to your health.
- Choose bookings that can be changed, where this is practical.
Cost, legal framework, and what a doctor must confirm
NK cell therapy is a self-pay (non-insured) treatment in Japan, so it is not covered by public health insurance. Travel, accommodation, and any interpreter needs are additional costs that you should add to your own planning. Please ask the clinic for a clear explanation of fees for each stage before you decide, and ask what is and is not included.
In Japan, this type of therapy is provided under the Act on the Safety of Regenerative Medicine, through a plan that is submitted to and accepted by the authorities. This framework is meant to support careful management of how cells are handled, but it is not a statement that any treatment will work for a particular person. Whether NK cell therapy is appropriate for you, along with its risks, possible side effects, and limits, can only be determined by a doctor after a consultation and review of your medical information.
Questions to bring to your consultation
A short, written list helps you use the consultation well, especially if you are communicating across languages. Consider asking about the evidence for NK cell therapy in your situation and what is still uncertain, how the therapy would fit alongside your current standard treatment, what side effects you should watch for after an infusion, and who you can contact if you feel unwell once you are back home.
It is also reasonable to ask how follow-up will work if you live abroad, and how information can be shared with your own doctors. Having a clear plan for communication can make the experience less stressful, and it supports the people responsible for your overall care.
Summary
NK cell therapy at Grand Green Osaka Umekita Clinic is structured around a blood draw and an IV infusion without hospitalization, which may make it easier to fit around daily life than a treatment requiring an inpatient stay. Even so, the number of visits, the timing between steps, and your own response need to be discussed with a doctor, and international patients benefit from planning travel only after an initial consultation. NK cell therapy is a self-pay option, provided under Japan’s regenerative medicine law, and it is not a replacement for standard cancer treatment. Please consult a doctor to find out whether it may be suitable for you, and to confirm costs, risks, and side effects before making a decision.
- 1ConsultationOnline first, if possible
- 2Blood drawStandard blood collection
- 3Cell processingTakes time between visits
- 4IV infusionNo hospital stay
This diagram is a conceptual summary of the article content
References
- PubMed: The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients. (1998)
- PubMed: Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels. (2003)
- PubMed: Effector mechanism and clinical response of BAK (BRM-activated killer) immuno-cell therapy for maintaining satisfactory QOL of advanced cancer patients utilizing CD56-positive NIE (neuro-immune-endocrine) cells. (2001)
- PMC: Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. (2019)
- PMC: Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions. (2013)
- PMC: Human cell-based artificial antigen-presenting cells for cancer immunotherapy. (2014)
- PMC: Case Report: Cord blood-derived natural killer cells as new potential immunotherapy drug for solid tumor: a case study for endometrial cancer. (2023)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.